ESG
Environment, Safety & Health

Environmental
Social
Governance

ESG

Environment, Safety & Health
Governance
Safety & Health
Environmental
Climate Change

Safety and Health Management


Given that our business inherently involves handling hazardous chemicals and fine chemical synthesis processes, thorough safety and health management is a core task for maintaining business continuity. A serious accident can not only delay new-drug production schedules but also lead to legal and financial sanctions, exerting a major impact on overall corporate operations.
Accordingly, ST Pharm has established a safety and health management system led by the Chief Safety Officer (CSO), operates Process Safety Management (PSM) and regular risk assessments, and proactively manages potential hazards through near-miss identification and improvement activities. This safety management system protects our employees while serving as a foundation for continuously securing the trust of global clients.

Environmental Management
 

For ST Pharm, whose processes involve handling hazardous chemicals, systematic environmental management is essential to maintaining business continuity. Inadequate environmental management may lead to exceedances of pollutant emission standards or environmental accidents, which could result in regulatory sanctions and a decline in client trust, negatively affecting corporate competitiveness. Meanwhile, the CDMO industry has a business structure in which the products manufactured and production processes vary depending on each client’s project requirements. As a result, environmental impact indicators, such as waste generation, are highly variable, creating certain constraints in setting a consistent baseline for environmental performance, including waste reduction. In response, we are strengthening our environmental management capabilities by introducing an Internet of Things (IoT)-based environmental operations system and a regenerative thermal oxidizer (RTO), and by operating an in-house treatment system for process waste liquids. This proactive environmental management system enhances regulatory responsiveness and helps build trust with global clients, supporting a foundation for long-term growth.

EHS Governance

Category
Organization
Leadership
Composition
Roles & Responsibilities
Highest Decision-
Making Body
Board of Directors
Chairman
Internal Directors
Outside Directors
  • Review and approve EHS management goals, plans, and performance
Company-wide Oversight Committee
Social Responsibility
Management Committee
CEO
Management
  • Review and approve EHS-related matters
  • Evaluate EHS performance (KPIs) and review and approve goals
Working-Level Committee
EHS Management Committee
Chief Safety Officer
C-level
  • Determine organization, personnel, and budget for EHS management
  • Approve EHS policy
  • Approve improvement measures for hazards and risk factors
Subcommittees
EHS Committee
-
-
  • Communication body for maintaining and promoting EHS
Safety and Health Council
-
-
  • Communicate with employees of subcontractors
  • Support the smooth operation of subcontractors
Implementing
Organization
Sustainability Management
Team
-
-
  • Oversee and manage EHS management activities
  • Maintain a system of reporting to the Chief Safety Officer
EHS Team
-
-
  • Operate the EHS management system
Facility Operation & Supporting Team
-
-
  • Operate the EHS management system
R&D Administration Team
-
-
  • Operate the EHS management system
HR & General Affairs Team
-
-
  • Implement office EHS measur

 

Safety Health and Environment (EHS) Policy
 

ST Pharm declares that we will fulfill corporate social responsibility by complying with the obligation to secure a safety and health environment across all business areas based on the management philosophy of respect for life.
 
  1. Establish and operate the company regulations to comply with safety, health and environment related laws, international agreements, and client requirements.
  2. Through the identification and improvement of potential hazards and risk factors, we take first into account of the safety and health environment throughout the entire process, from product design, production, distribution, use, up to disposal.
  3. To achieve the goal of the safety and health environment, we strengthen investment activities and make active efforts to save resources and promote recycling.
  4. To make a safe working environment, we secure the process safety technology and emergency response system based on preventive activities.
  5. We actively participate in the activities for community safety and health environment and take the leading role in promoting the safety and health environment of the local community.

 

Health, Safety and Environment Policy    PDF
Environmental Policy

 

Environmental Management Goals

 

Climate Change Roadmap

Health & Safety Management Goals

Safety and Health Risk Management

 
ST Pharm applies a systematic Process Safety Management (PSM) system designed to prevent serious safety accidents that may occur in the process of handling or manufacturing hazardous substances. Based on this system, we systematically manage our business sites through risk assessment, the preparation of Standard Operating Procedures (SOPs) and operation manuals, safety management of facilities and equipment, training, and emergency response plans.
Risk Assessment
ST Pharm conducts ad hoc and regular risk assessments to identify, correct, and prevent safety and health risks across the entire business. Regular assessments are conducted annually, dividing the overall business into equipment, process, and work areas to identify and improve hazards and potential accidents. Ad hoc assessments are conducted when there are new introductions or changes to equipment, raw materials, work methods, and the like, targeting work in which additional hazards may arise. The risk assessment results and the corresponding corrective-action status are shared with all employees at the business site, and the effectiveness of corrective actions is confirmed through reassessment after improvement.
Following risk assessments, ST Pharm goes beyond simply recording the results by translating identified hazards into on-site improvements, thereby achieving meaningful improvements in safety.
 
Key Improvements
Hazard
Improvement
Risk of worker burns due to high-temperature exposure of the water-for-injection piping at the sampling point on the first floor of the Oligo Plant
Installation of insulation/protective covers on piping
blocking direct contact)
Risk of accidents due to tipping over and impact while moving measurement equipment
Provision of a dedicated transport cart with side-protection structure (securing stability)
Risk of ground collapse and forklift tipping due to damage to the asphalt around an outdoor manhole
Re-paving of asphalt (securing ground stability)
Risk of falling due to the open structure of the work area for loading finished products for disposal
Installation of safety railings in the work area (physical protective measure)
Emergency Response System
ST Pharm operates an emergency control organization at each business site to respond promptly and systematically to emergencies and minimize human and material damage. When an emergency occurs, we carry out initial response in accordance with the Emergency Response Plan (ERP) and establish measures to prevent recurrence through accident investigation and cause analysis.
In the subsequent recovery stage, we review and activate the Business Continuity Plan (BCP) to minimize production disruptions and secure business continuity. Based on this stage-by-stage response system, we manage the entire process from accident occurrence to recovery and follow-up monitoring, and strengthen our emergency response capabilities through continuous improvement.
Safety and Health Management for Partners
ST Pharm conducts regular risk assessments for on-site subcontractors and continuously improves and manages the working environment through joint safety and health inspections in which the Safety and Health Management Officer of each campus participate. Through this, we have established a system to quickly identify hazards that may arise on site and to prepare effective improvement measures.
On-Site Hazard Management

Workplace Inspection
To prevent safety accidents in its facilities and workplaces, ST Pharm regularly undergoes both internal self-inspections and external inspections performed by specialized organizations. Depending on the purpose and target of the inspection, various inspectors check firefighting facilities and working environments to ensure workplace safety. All inspection findings are documented, and any problems discovered are subject to corrective action procedures. In addition, we meet the standards of safety and health management during the audit by various global clients, advancing the level of safety and health management. 
 
Operation of a Work Permit System
ST Pharm operates a work permit system for work with potential hazards, thoroughly implementing preventive safety measures in advance. By verifying compliance with the safety standards established for each type of work before proceeding, we block the possibility of industrial accidents in advance.
 
Near-Miss Identification and Improvement
ST Pharm operates a "potential hazard identification card" to identify potential hazards that may arise in everyday work environments at an early stage. By identifying situations that could have led to an accident or unsafe conditions during the risk assessment process and recording and managing the corresponding improvement measures, we continuously improve the level of on-site safety.
Worker Health Management
Establishment of a Health Management Office
To protect employees' health and provide systematic health management, ST Pharm has established a health management office and assigned an occupational nurse to provide professional health management services.
 
Respiratory Protective Equipment Fit Test
To provide employees with optimal respiratory protective equipment, ST Pharm conducts a Fit Test for all employees. New hires undergo a suitability test upon joining, and existing employees also undergo regular Fit Tests, through which we select protective equipment suited to each individual's face shape and provide training on proper wearing methods. This helps prevent the risk of chemical exposure and respiratory disease.
 
Work Environment Management
ST Pharm regularly conducts work environment measurements to identify and improve exposure levels to hazards such as the chemicals it handles, noise, and dust. Based on the measurement results, we manage and improve hazards in the workplace. In addition, we perform chemical risk assessments every half-year to evaluate the hazards and risks that chemicals pose to the human body, and minimize potential exposure risks through necessary reduction measures. Furthermore, to prevent the spread of contaminants within the work environment, we regularly inspect local exhaust ventilation systems.
 
Medical Checkup Support
ST Pharm conducts regular medical checkups for all employees and supports the cost of these checkups. For those with findings from the checkups, we operate systematic follow-up management programs such as lifestyle improvement guidance, health management counseling, and tracking observation. In addition, we conduct risk assessments to prevent cerebrovascular and cardiovascular diseases, and post health materials on in-house bulletin boards and at the entrance of the cafeteria to raise awareness of disease prevention and health management.
 
Musculoskeletal Disorder Prevention
ST Pharm conducts a musculoskeletal risk factor survey every three years to help prevent musculoskeletal disorders among workers. We review burdensome tasks and symptoms based on work methods and work intensity, and according to the investigation results, we identify the departments to be managed and pursue improvements to the working environment. In addition, we provide prevention education such as stretching and proper postures for handling heavy objects, and for employees reporting pain, we provide individual counseling and implement measures to improve work methods.
 
Mental Health Management
ST Pharm conducts a job-stress assessment every three years to manage employees' job stress and promote their psychological health. The assessment uses the Korean Occupational Stress Scale (KOSS) to systematically diagnose key stress factors such as job autonomy, the reward system, and organizational culture. We also operate job-stress management training every year.
Safety and Health Training and Drill
 
Training
ST Pharm operates safety and health training based on the characteristics of each job as well as specialized safety and health training programs for specific managers, and conducts special training when additional safety and health management is deemed necessary.
In addition, to verify the effectiveness of safety and health training, we conduct regular training assessments. The Sihwa and Banwol Campuses conduct assessments once a year based on the content of regular and special training, and re- training is provided to those who fail to meet the threshold score (70 or higher out of 100). The Seoul Campus operates a quiz-format assessment once every half-year, requiring participants to score at or above the threshold to complete the course, thereby continuously strengthening employees' safety and health competencies.
 
Drills
ST Pharm conducts emergency response drills and firefighting drills every year to make safety awareness part of everyday life at our business sites and to respond promptly to disasters such as fire, explosion, leakage, and power outage, as well as natural disasters. By establishing emergency response scenarios for each department and regularly conducting in-house drills, we strengthen practical response capabilities.
 
Safety and Health Training and Drill Framework
Classification
Training Content
Period
Work-related training
 Training at hiring and job transfer At hiring and job transfer
Regular safety and health training Once a month
EHS SOP training At the establishment/revision of SOP
Process Safety Management (PSM) training  Once a quarter
On-site subcontractor / visitor training When visiting
Specialized training
 EHS manager statutory training As required by applicable law
Development training As required by applicable law
Drill
 Fire drill Once a year
Emergency response drill Once a year
Confined space rescue drill  Once every six months

Safety and Health Performance Indicators

 

Injuries and Illnesses
Category
 Unit 2023 2024 2025
Employees
Total annual working hours1)
 hours 1,612,800 1,648,800 1,872,000
Total injuries
 cases 12 15 19
   Work-related fatalities
 cases 0 0 0
   Serious work-related injuries2)
 cases 0 0 0
Work-related
injuries
 Occupational accidents3) cases 1 1 3
Safety incidents4) cases 11 14 16
Lost time injury frequency rate, LTIFR5) cases (occupational accidents per 1 million working hours) 0.62 0.61 1.60
Lost time injury severity rate, LTISR5) days (lost days per 1,000 working hours) 0.06 0.13 0.26
Work-related disease fatalities cases 0 0 0
Cases of work-related illness cases 0 0 0
Partners6) Total annual working hours1) hours 72,000 72,000 76,800
Total injuries cases 0 0 0
    Work-related fatalities cases 0 0 0
    Serious work-related injuries2) cases 0 0 0
     Work-related injuries cases 0 0 0
Work-related disease fatalities cases 0 0 0
Cases of work-related illness cases 0 0 0
1) Total annual working hours = [annual working days (300 days) x working hours per day (8 hours)] x total number of employees and partner workers
2) Number of serious accidents (serious industrial accidents) excluding fatalities
3) Accidents approved by the Korea Workers' Compensation & Welfare Service (accidents requiring 3 or more days of medical treatment)
4) General safety incidents received other than occupational accidents (differs from the previous year's report due to duplicate counting of 2024 data)
5) Figures differ from the previous year's report due to data recalculation
6) For on-site Partners (subcontractors: cafeteria, cleaning, security, wastewater) at ST Pharm business sites

Hazard Risk Management
Category
Unit
2023
2024
2025
Equipment risk1)
Assessment target
cases
61
63
80
Identified factors
cases
42
42
50
Improvement (implementation rate)
cases (%)
42(100)
42(100)
48(96)
Process risk1)
Assessment target
cases
13
12
17
Identified factors
cases
22
12
6
Improvement (implementation rate)
cases (%)
22(100)
12(100)
6(100)
Work risk2)
Assessment target
cases
40
39
41
Identified factors
cases
50
79
57
Improvement (implementation rate)
cases (%)
50(100)
79(100)
56(98)
1) Equipment and process risk: Sihwa and Banwol Campuses
2) Work risk: Sihwa, Banwol, and Seoul Campuses

Environmental Management

 
Water Resources Management
ST Pharm conducted a water stress analysis using the WRI Aqueduct tool and OECD research literature¹⁾ to identify and manage impacts on water resources arising from our business operations. The analysis found that Gyeonggi-do, South Korea, where our Sihwa and Banwol manufacturing campuses are located, was identified as an area with “low-medium” water stress. Based on these findings, we established a water resources management strategy optimized for regional characteristics. We also minimize impacts on aquatic ecosystems by effectively treating wastewater generated at our business sites and operating a strict discharge management system.
 
Wastewater Management
To remove pollutants from wastewater generated by manufacturing processes, ST Pharm operates a three-stage advanced treatment process at our in-house wastewater treatment plant, consisting of primary physicochemical treatment, secondary biological treatment, and tertiary membrane filtration. The treated wastewater passes through a public sewage treatment plant and is finally discharged into the Yellow Sea. Before discharge, we regularly analyze and measure pollutants, register and manage newly identified pollutants, and strictly comply with regulatory limits. We also apply internal control limits set at 90% of applicable regulatory limits
 
Water Quality Monitoring
ST Pharm has established internal control limits that are stricter than regulatory limits to proactively manage water pollutants. We measure total organic carbon (TOC) and pH in raw water, wastewater, and effluent on a daily basis, and continuously monitor and manage water quality through monthly analyses conducted by an external specialized institution. In particular, in 2025, we established an internal target to maintain total nitrogen (TN) discharge levels from the wastewater treatment plant below 80% of the regulatory limit. We also introduced high-precision TN measurement equipment to continuously monitor influent and effluent concentrations and maintain them within our internal target.

Water Resources
Category Unit 2023 2024 2025
Total water withdrawal tonnes 184,583 190,258 202,578
   Potable water Total tonnes 133,683 151,325 165,937
        Sihwa Campus tonnes 11,477 16,195 15,813
        Banwol Campus tonnes 120,773 133,942 149,199
        Seoul Campus tonnes 1,433 1,188 925
   Industrial
   water		 Total tonnes 50,900 38,933 36,641
        Sihwa Campus tonnes 38,509 30,028 28,728
        Banwol Campus tonnes 12,391 8,905 7,913
        Seoul Campus1) tonnes 0 0 0
   Total water
   discharge		 Total tonnes 75,442 79,827 89,241
        Sihwa Campus tonnes 31,559 28,533 29,386
        Banwol Campus tonnes 43,883 51,294  59,855
        Seoul Campus1) tonnes 0 0 0
Total water consumption²⁾ Total tonnes 109,141 110,431 113,337
        Sihwa Campus tonnes 18,427 17,690 15,155
        Banwol Campus tonnes 89,281 91,553 97,257
        Seoul Campus tonnes 1,433 1,188 925
    Water consumption in water-stress areas tonnes 0 0 0
    Water consumption in products³⁾ tonnes 0 0 0
Total water reuse⁴⁾ Total tonnes 12,607 13,056 19,041
        Sihwa Campus tonnes 2,869 4,049 3,953
        Banwol Campus tonnes 9,738 9,007 15,088
        Seoul Campus tonnes 0 0 0
Water withdrawal intensity⁵⁾ tonnes/KRW 100 million 64.8 69.5 61.1
1) The Seoul Campus is an office facility, and data on industrial water withdrawal and water discharge are not collected. Accordingly, the figures are reported based on the Sihwa and Banwol Campuses, which include manufacturing facilities.
2) Water consumption = water withdrawal − water discharge (water containing organic solvents generated in processes (wastewater: water + organic solvents) is consigned for treatment, and the amount of water contained in wastewater is excluded from water discharge because it cannot be quantified).
3) The water content in our products is 0.
4) Concentrated water generated during purified water production is fully recovered and reused as industrial water (2023 and 2024 Sihwa Campus data differ from the previous report due to recalculation).
5) Water withdrawal intensity = total water withdrawal / consolidated revenue.
 
Water Pollutants
Category
Unit
2023
2024
2025
Total emissions of water pollutants
tonnes
2.632
1.030
2.128
   Biochemical Oxygen Demand (BOD)
Total
tonnes
0.128
0.198
0.216
    Sihwa Campus
tonnes
0.038
0.168
0.184
    Banwol Campus
tonnes
0.090
0.030
0.032
    Seoul Campus1)
tonnes
0
0
0
   Total Organic Carbon (TOC)
Total
tonnes
0.280
0.419
0.390
    Sihwa Campus
tonnes
0.140
0.199
0.188
    Banwol Campus
tonnes
0.140
0.220
0.202
    Seoul Campus1)
tonnes
0
0
0
   Total Nitrogen (TN)
Total
tonnes
2.166
0.375
1.452
    Sihwa Campus
tonnes
0.056
0.155
0.027
    Banwol Campus
tonnes
2.110
0.220
1.425
    Seoul Campus1)
tonnes
0
0
0
   Suspended Solids (SS)
Total
tonnes
0.058
0.038
0.070
    Sihwa Campus
tonnes
0.038
0.008
0.016
    Banwol Campus
tonnes
0.020
0.030
0.054
    Seoul Campus1)
tonnes
0
0
0
1) The Seoul Campus is an office facility, and does not discharge water pollutants.
Soil Pollution Management
ST Pharm recognizes soil environment conservation and pollution accident prevention as core environmental management elements, and systematically operates a prevention-focused management process that exceeds legal standards. Through regular soil contamination inspections, we received a “conforming” determination in 2025, proving the safety of our soil environment, and built a three-stage composite protection system to prevent the spread of and rapidly respond to pollution accidents. We continue to strengthen our soil pollution prevention and response capabilities through ongoing facility improvements and monitoring, thereby creating safe and sustainable business sites.
Air Pollutant Management
ST Pharm operates a transparent management system for the systematic management and reduction of air pollutants, and we have established and thoroughly apply internal control limits that are stricter than regulatory limits. We identify all air emission sources and conduct regular monthly monitoring and pollutant analyses. We also minimize impacts on air quality by installing and operating optimized air pollution control facilities at each emission source/facility. In addition, we conduct exhaust gas analyses twice a month through external specialized service providers and carry out continuous monitoring and facility improvements.
 
IoT-Based Environmental Operating System
ST Pharm introduced an environmental operating system using Internet of Things (IoT) technology to monitor the operating status of emission and prevention facilities in real time. The collected information is transmitted in real time to the Korea Environment Corporation, securing transparency and reliability in air pollution management.
 
Installation of Air Pollution Control Facilities - RTO
With the construction of the 2nd Oligo Plant at the Banwol Campus, ST Pharm newly installed a regenerative thermal oxidizer (RTO) and a complex tower, and completed the operation commencement report. The RTO minimizes emissions of total hydrocarbons (THC) and volatile organic compounds (VOCs). Through self-monitoring of the RTO, we manage THC levels below the regulatory limit of 200 ppm.

Odor Measurement and Reduction Management
ST Pharm’s manufacturing sites conduct monthly self-monitoring of odors to verify compliance with applicable standards, and odor levels measured in 2025 were maintained below 80% of regulatory limits.

Air Pollutants
Category
Unit
2023
2024
2025
Total emissions of air pollutants
tonnes
25.129
14.657
22.018
    Dust
Total
tonnes
0.431
0.960
1.243
    Sihwa Campus
tonnes
0.335
0.535
0.383
    Banwol Campus1)
tonnes
0.096
0.425
0.860
    Seoul Campus2)
tonnes
0
0
0
    Sulfur Oxides (SOx)
Total
tonnes
0.442
0.276
0.446
    Sihwa Campus
tonnes
0.442
0.276
0.347
    Banwol Campus
tonnes
0.000
0.000
0.099
    Seoul Campus2)
tonnes
0
0
0
    Nitrogen Oxides (NOx)
Total
tonnes
1.163
0.797
0.738
    Sihwa Campus
tonnes
1.163
0.797
0.738
    Banwol Campus
tonnes
0
0
0
    Seoul Campus2)
tonnes
0
0
0
    Total Hydrocarbons (THC)
Total
tonnes
23.093
12.624
19.591
    Sihwa Campus
tonnes
20.740
8.461
12.746
    Banwol Campus1)
tonnes
2.353
4.163
6.845
    Seoul Campus2)
tonnes
0
0
0
1) 2023 and 2024 data differ from the previous report due to recalculation.
2) The Seoul Campus is an office facility, and does not emit air pollutants.
Waste Management
ST Pharm manages organic solvents, process waste liquids, etc. generated from our API manufacturing processes as major waste, and strives to improve resource efficiency and reduce waste generation throughout the entire process from product production to disposal. Some waste includes hazardous characteristics such as flammability and toxicity, which can pose risks of environmental pollution and safety accidents if not properly managed. Accordingly, we store, transport, and treat waste in accordance with our waste management SOP¹⁾ to comply with regulatory requirements and minimize environmental and safety risks. We also classify waste by type at our manufacturing sites, calculate the amount generated and discharged, and register it in “Allbaro,” the national waste management system, for transparent management. In 2025, we reorganized our management process by separating contract management from on-site management to enhance objectivity in the management of waste treatment service providers.


 

Climate Change Response Strategy


As physical and transition risks associated with climate change increase, companies that fail to establish appropriate climate change response strategies are increasingly likely to suffer financial losses. 
Overview of Scenario Analysis
ST Pharm continuously monitors the global environment and deeply understands the impact of climate change on corporate sustainability and management activities. For this reason, we conducted a climate change scenario analysis to systematically evaluate the risks and opportunities posed by climate change to our business operations and proactively manage them. In the process of scenario analysis, we secured the validity of the analysis through interviews with external experts and a climate change scenario analysis workshop, and applied various future climate change scenarios to assess the potential impact on our operations and establish response strategies.

Climate Risk Analysis Results
ST Pharm conducted scenario-based assessments of the 25 selected climate change risks, analyzed the risk patterns under the 1.5°C and 4.0°C scenarios, and derived changes by period (short-term (~2030), medium-term (~2040), and long-term (~2050)) and the impact on business operations. In the 1.5°C scenario, climate change risk patterns revealed a significant surge in policy and regulatory risks, as well as an ongoing increase in transition risks. In the 4.0°C scenario, physical climate risks were increased sharply, and market and supply chain risks continued to grow.

Climate Risk Management Framework
ST Pharm has set short-, medium-, and long-term time horizons for responding to climate change, and conducted scenario analyses accordingly. In detail, we have systematically analyzed climate change scenarios up to 2050, taking into account the achievement of our net zero carbon emissions target. Through this analysis, we assess the impact of climate change on our business operations and develop response strategies for sustainable growth. The analysis results will serve as an important basis for setting GHG reduction targets and establishing implementation plans, and will contribute to minimizing climate change risks in the long term.

Climate-Related Targets

 
Establishing Science-Based GHG Reduction Targets
ST Pharm supports the Science Based Targets initiative's (SBTi) target of reaching net-zero by 2050, and as part of this, has made a commitment to SBTi Services to set near-term targets in February 2025. In accordance with the SBTi guidance, we have set a near-term reduction target (SBT) aimed at achieving reductions by 2035, and will seek verification and approval of the target in the future. Our GHG reduction target includes Scope 1 (direct emissions), Scope 2 (indirect emissions), as well as emissions from categories 1, 3, and 5, which account for approximately 95% of our total Scope 3 (other indirect emissions) emissions.
We aim to reduce our Scope 1 & 2 emissions by 63% (based on 1.5° C) and our Scope 3 emissions by 37.5% (based on WBC2) by 2035 compared to the baseline year. Going forward, ST Pharm plans to establish specific Scope 1, 2 and 3 reduction strategies based on the SBTs, which will drive company-wide implementation activities to achieve net-zero.

 
GHG Emissions1)
Category
Unit
2023
2024
2025
Total emissions (Scope 1+2+3)
tCO₂eq
77,889
79,232
94,795
Scope 1 emissions
Total
tCO₂eq
394
422
1,227
    Sihwa Campus
tCO₂eq
275
310
436
    Banwol Campus
tCO₂eq
28
37
732
    Seoul Campus
tCO₂eq
92
75
59
Scope 2 emissions
Total
tCO₂eq
23,835
25,705
29,497
    Sihwa Campus
tCO₂eq
5,745
6,135
6,096
    Banwol Campus
tCO₂eq
17,967
19,451
23,283
    Seoul Campus
tCO₂eq
123
119
119
Scope 3 emissions
Total
tCO₂eq
53,660
53,105
64,072
  C1. Purchased goods and services2)
tCO₂eq
39,629
36,156
47,612
  C2. Capital goods
tCO₂eq
17
27
36
  C3. Fuel- and energy-related
  activities not included in Scope 1 and  22)
tCO₂eq
7,034
7,708
8,764
  C4. Upstream transportation
  and distribution2)
tCO₂eq
662
696
462
  C5. Waste generated in operations2)
tCO₂eq
4,628
6,937
5,720
  C6. Business travel
tCO₂eq
284
331
266
  C7. Employee commuting
tCO₂eq
848
874
974
  C9. Downstream transportation
  and distribution
tCO₂eq
65
74
33
  C10. Processing of sold products
tCO₂eq
493
302
204
GHG emissions intensity3) (Scope 1+2)
tCO₂eq/KRW 100 million
8.502
9.544
9.263
Intensity change
tCO₂eq/KRW 100 million
(0.09)
1.04
(0.28)
Intensity change rate
%
(1.02)
12.26
(2.95)
1) Differences of less than ±1 tCO2eq may occur due to rounding for reporting GHG emissions as integers.
2) 2023 and 2024 data differ from the previous report due to recalculation.           
3) Emissions intensity = Scope 1+2 GHG emissions / consolidated revenue.
 
Energy Consumption
Category
Unit
2023
2024
2025
Total energy consumption
TJ
244.7
267.1
309.5
Non-renewable energy consumption
TJ
244.7
267.0
309.4
Fuel
Total
TJ
5.8
7.0
12.1
    Sihwa Campus
TJ
3.9
5.2
7.3
    Banwol Campus
TJ
0.5
0.7
3.9
    Seoul Campus
TJ
1.4
1.1
0.9
Electricity1)
Total
TJ(kWh)
136.0(37,754,403)
146.1(40,585,393)
170.2(47,246,405)
    Sihwa Campus
TJ(kWh)
40.7(11,297,412)
43.1(11,965,824)
41.8(11,598,516)
    Banwol Campus
TJ(kWh)
94.3(26,188,944)
102.1(28,360,542)
127.5(35,400,624)
    Seoul Campus
TJ(kWh)
1.0(268,047)
0.9(259,027)
0.9(247,264)
Heat (steam)
Total
TJ
102.9
113.9
127.1
    Sihwa Campus
TJ
24.3
29.5
33.2
    Banwol Campus2)
TJ
78.6
84.4
93.9
    Seoul Campus
TJ
0
0
0
Renewable energy consumption
TJ(kWh)
0.03(8,537)
0.04(11,025)
0.04(10,794)
    Sihwa Campus
TJ(kWh)
0
0
0
    Banwol Campus
TJ(kWh)
0.03(8,537)
0.04(11,025)
0.04(10,794)
    Seoul Campus
TJ(kWh)
0
0
0
Proportion of renewable energy consumption
%
0.023
0.027
0.023
Solar power generation³⁾
kWh
8,537
11,025
10,794
Energy intensity⁴⁾
TJ/KRW 100 million
0.086
0.098
0.093
1) A conversion factor of 3.6 GJ/MWh is applied to electricity consumption.
2) 2023 and 2024 data differ from the previous report due to recalculation.
3) Solar power generation is fully consumed as renewable energy.
4) Energy intensity = total energy consumption / consolidated revenue.
5) The Scope 3 target covers categories 1, 3, and 5, which account for about 95% of total Scope 3 emissions.

GHG Reduction Target
Category Unit 2024 Base Year 2025 Actual Target
2030 2035 2050
Scope 1&2 tCO₂eq 26,127 30,725 17,161 9,674 0
Scope 3 tCO₂eq 53,105 64,071 36,177 28,425 0

Biodiversity


Biodiversity Management System
ST Pharm recognizes biodiversity as an important element of environmental management and considers it in its efforts to build a sustainable management system. For this reason, we establish a biodiversity management strategy in stages based on the Locate, Evaluate, Assess, Prepare (LEAP) methodology of the Taskforce on Nature-related Financial Disclosures (TNFD). The LEAP approach is an internationally recognized framework that helps companies systematically assess their dependencies and impacts on nature and, based on this, prepare effective management and response measures. We are currently in the early stages of the process, focusing on understanding the ecological characteristics of the regions where our business sites are located and building a foundational database for more precise assessments going forward.
 
Biodiversity Management Process
Completed
 
Locate
 Locate and identify
ecologically sensitive areas
  • Assess the biodiversity risk of the region  (landscape) where the business site is located 
  • Identify nearby protected areas and endangered species
 
↓
 
  
 
Evaluate
 Impact and dependency
ssessment of identified areas
  • Use the ENCORE tool
  • Assess impacts and dependencies by industry classification
 
 
↓
 
  
Planned
 
Assess
 Nature-related risk and opportunity assessment
  • Determine the need for management actions based on impact and dependency assessment results
  • Select key issues
 
↓
 
  
 
Prepare
 Response and reporting
  • Derive improvement tasks related to key issues
  • Disclose biodiversity-related performance and targets

You can transparently view the results of our 2025 assessments in the '2025 Sustainability Report.' Throughout the year, we completed site-level risk assessments, identified nearby protected areas and endangered species, and evaluated our nature-related impacts and dependencies.
HOMEESGEnvironment, Safety & Health
© 2026 ST Pharm. All rights reserved.

We care about your privacy

This site uses essential cookies necessary for the operation of the service and for maintaining your language preferences. For more information, please review our Privacy Policy and Terms of Service.